HAMPTON, England--(BUSINESS WIRE)--Touchlight, a CDMO enabling the development of genetic medicines with its enzymatic doggybone DNA (dbDNA) technology, today announced that the Company has used its ...

The genetic medicine revolution is underway. Just 18 months ago, very few people in the general population had heard of mRNA vaccines; now, hundreds of millions globally have been vaccinated with one.

The molecular cloning workflow requires QC checkpoints both before and after restriction endonuclease digestion to minimize ...

According to Nova One Advisor, the global viral vector & plasmid DNA manufacturing size is calculated at USD 7.54 billion in 2025 and is expected to surpass around USD 27.71 billion by 2034, growing ...

DUBLIN--(BUSINESS WIRE)--The "Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering. Overall world revenue for the viral vectors ...

Ara Hacobian Ph.D. Head of Molecular Biology Ludwig Boltzmann Institute for Experimental and Clinical Traumatology David Hercher Ph.D. Master of Science Ludwig Boltzmann Institute for Experimental and ...

Touchlight scored another $125 million to boost manufacturing as the company looks to become a leading synthetic DNA producer for genetic medicines. The cell and gene therapy space has exploded in the ...

To evaluate the immune responses of mice vaccinated intramuscularly with naked DNA encoding a single parasite-derived gene, sufficient quantities of protein are necessary for use in the immunological ...

Every dog has its day, and Monday was Curia’s as the CDMO got its paws on a new drug manufacturing platform. Curia has enlisted enzymatic DNA production outfit Touchlight to furnish its clients with ...